Maraviroc in the treatment of HIV infection.

Maraviroc in the treatment of HIV infection.

Item
http://www.wikidata.org/entity/Q37634319
Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug designGPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway.Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture.Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infectionThe effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer.Maraviroc attenuates trauma-hemorrhage-induced hepatic injury through PPAR gamma-dependent pathway in ratsAllosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).CCR5 as a treatment target in pulmonary arterial hypertension.
P2860

Maraviroc in the treatment of HIV infection.

Item
http://www.wikidata.org/entity/Q37634319
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Maraviroc in the treatment of HIV infection.
@en
Maraviroc in the treatment of HIV infection.
@nl
type
label
Maraviroc in the treatment of HIV infection.
@en
Maraviroc in the treatment of HIV infection.
@nl
prefLabel
Maraviroc in the treatment of HIV infection.
@en
Maraviroc in the treatment of HIV infection.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P478
P577
P698
P932
P356
P1433
P1476
Maraviroc in the treatment of HIV infection
@en
P2093
P2860
P304
P31
P356
P407
P478
P577
P698
P932